AN2 Therapeutics starts Phase 3 trial for epetraborole in refractory MAC lung disease

AN2 Therapeutics, Inc.

Phase 2 enrollment completed with 80 patients; topline Phase 2 data expected summer 2024.
Phase 3 part launched with over 100 sites in U.S., Japan, South Korea, Australia; plans to enroll ~230 patients.
Epetraborole is an oral, once-daily drug; FDA granted Fast Track, QIDP, and orphan drug designations.
No approved oral therapy currently exists for MAC lung disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.